Top shroom stocks under discussion in 2021

Follow us on Google News:
 Top shroom stocks under discussion in 2021
Image source: Poring Studio,Shutterstock

Summary

  • COMPASS Pathways Plc (Nasdaq: CMPS) has a market capitalization of CMPS is US$1.3 billion.
  • Seelos Therapeutics, Inc (Nasdaq: SEEL) was recently added to the first psychedelic stock ETF in the US called Defiance Next Gen Altered Experience.
  • ATAI Life Sciences N.V (Nasdaq: ATAI) received funds from Palo Santo, a leading psychedelic fund.

Shroom or psychedelic stocks are becoming mainstream as their importance in alleviating mental health issues has been proven. In addition, the coronavirus pandemic in 2020 underlined the importance of mental health as the crisis had threatened both mental and physical health.

Research has been done to understand how LSD, magic mushrooms, or other psychedelic drugs work for mental health. The Johns Hopkins University has launched the Centre for Psychedelic Research with US$17 million funding for research.

It is estimated that the shroom market will reach US$6.85 billion by 2027. As a result, many psychedelic companies are going public. Psychedelic mushrooms or MDMA, and LSD are banned in the US currently. However, the Oregon State has recently legalized psychedelics for therapeutic purposes. Therefore, more states might legalise psychedelics for therapeutic purposes as well.  

Also read: 5 junior pot stocks to explore as marijuana gets more support in US

Source: Pixabay.

COMPASS Pathways Plc (Nasdaq: CMPS)

COMPASS Pathways Plc, a mental health care company, tests whether a synthetic form of psilocybin can be used to treat depression.

Its stock was up 1.38 to US$36.70 at 8.56 am ET on July 27. The stock declined 23.61% YTD.

The market capital of CMPS is US$1.3 billion. The forward P/E 1 year is -24.15, and the beta is 3.95. CMPS’ 52-weeks highest and lowest stock price was US$61.69 and US$22.51, respectively.

Seelos Therapeutics, Inc (Nasdaq: SEEL)

Seelos Therapeutics, Inc is a biopharmaceutical company, develops therapies for nervous system disorders. Seelos was recently added to the US’ first psychedelic stock ETF called Defiance Next Gen Altered Experience.

Its stock traded at US$2.33 at 8.57 am ET on July 27, up by 0.87 percent over the previous closing price. Its stock prices decreased by 57.66 percent YTD.

SEEL’s market cap is US$255 million, the forward P/E 1 year ratio is -3.30, the beta is 3, and the EPS is US$-0.58. The 52 week highest stock price of SEEL is US$6.60, and the lowest is US$0.56. The share volume is 818,127.

The company on May 20 announced the price of its 19,354,840 stocks as US$60 million with US$3.10 per share.

Source: Pixabay.

ATAI Life Sciences N.V. (Nasdaq: ATAI)

ATAI Life Sciences N.V., a biopharmaceutical company, develops medicines to treat mental health issues. In addition, the company has a focus on developing psychedelic drugs to treat mental health problems.

Its stock was priced at US$16.95, up 4.31% from its previous close, at 8.59 am ET on July 27. The company launched its IPO on June 18 this year.

The market capitalization of ATAI is US$2.5 billion. The forward P/E 1 year is -34.08. The 52 week highest stock price of ATAI is US$22.91, and the lowest is US$16.50. The share volume is 208,328.

Palo Santo, a leading psychedelic fund, has recently funded US$35 million to 20 companies, including ATAI.

Mind Medicine (MindMed) Inc (Nasdaq: MNMD)

Mind Medicine (MindMed) Inc is a leading psychedelic biomedicine company.

Its stock traded at US$3.06 at the premarket on July 27. The stock prices of MNMD went up by 0.82 percent YTD. 

The market capital of MNMD is US$1 billion. The beta is -12.75. The 52 week highest stock price of MNMD is US$5.77, and the lowest is US$2.85. The share volume is 4,054,838.

The company started to list on Nasdaq on April 27 this year. And it would continue to be listed on NEO Exchange under the ticker MMED. In addition, MNMD has been added to the FTSE Russell 3000® index in June this year.

Ehave Inc (OTC: EHVVF)

Ehave Inc, a digital therapeutics firm, delivers medicines with ketamine infusion at home. Its stock traded at US$0.0415 at at the premarket on July 26, up by 27.3 percent over the previous closing price. Its share volume is 207,746. The company March, this year, listed its shares on the OTCQB market.

Small Pharma (Other OTC: DMTTF)

Small Pharma (DMTTF) is a UK-based pharmaceutical company. It is developing a rapid treatment for depression. It has a market cap of US$123 million.

The stock price was down 5.83% to US$0.3767 in the premarket session on July 27. The market cap of DMTTF is US$100 million.

Cybin Inc (Other OTC: CLXPF)

Cybin Inc, a biotechnology company, focuses on psychedelic therapy for mental health disorders. The stock was priced at US$3.11, up 3.67% from the previous close, in the premarket session on July 27. The market cap is US$503.85 million.

The company reported a net loss of US$32 million in the fiscal year ended on March 31. Non-cash expenses were US$1 million, and cash-based expenses were US$19 million. It had cash and cash equivalents of US$64 million this year.

Also read: 10 cannabis stocks in focus

Numinus Wellness Inc. (Other OTC: LKYSF)

Numinus Wellness Inc, A Canada-based healthcare company, is creating health solutions focused on the evidence-based use of psychedelic-based therapies. 

Numinus stock was down 0.42% to US$0.7568 in premarket session on July 27. Its share volume is 417,807. The company recently announced that it has started to grow Psilocybe mushrooms at its lab for research.

Please note: The above constitutes a preliminary view and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles